因弗利克西马布是一种安全有效的治疗类固醇耐药性免疫相关肝炎的治疗方法
Kim Nikola Oliva1, Lisa Arnold2,3, Lucie Heinzerling2,3
1Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
恩弗利西马布是一种安全有效的治疗严重的免疫相关性肝炎 (ir肝炎),不响应类固醇. 这项研究发现,因肝炎治疗的患者没有因因弗利克西马布相关的肝损伤.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 严重的免疫相关性肝炎 (ir肝炎) 发生在15-20%的接受伊皮利姆巴和尼沃姆巴联合治疗的患者中.
- 目前的指导方针建议使用皮质类固醇,对于耐固醇病例的选择有限.
- 尽管有有希望的病例报告,但TNF-α抑制剂Infliximab通常不建议治疗肝炎.
研究的目的:
- 评估infliximab在治疗类固醇耐药性肝炎的安全性和有效性.
- 评估infliximab对该患者群体肝脏毒性的影响.
主要方法:
- 对28名患有晚期皮肤黑色素瘤和肝炎的患者进行了多中心回顾性分析.
- 患者接受了伊皮利穆马布加尼沃卢马布,随后接受了因弗利克西马布治疗类固醇耐药性肝炎.
- 收集关于治疗反应,皮质类固醇逐渐减少和不良事件的数据.
主要成果:
- 92.9%的患者在因弗力西马布治疗后实现了临床缓解 (≤CTCAE级1).
- 在82.1%的患者中,皮质类固醇的缓解成功.
- 在349天的中位数随访期间,没有观察到死亡或因弗力西马布相关的肝损伤.
结论:
- 因弗利克西马布是一种安全有效的选择,用于与类固醇耐药性免疫相关的肝炎.
- 治疗显示了高的临床缓解率,没有肝毒性.
- 进一步的研究可能会支持infliximab在治疗严重肝炎中的作用.
更多相关视频
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
